Attached files
file | filename |
---|---|
EX-99.1 - EX-99.1 - ONYX PHARMACEUTICALS INC | f54083exv99w1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 16, 2009
ONYX PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
DELAWARE | 0-28298 | 94-3154463 | ||
(State of incorporation) | (Commission File No.) | (IRS Employer Identification No.) |
2100 Powell Street
Emeryville, California 94608
(Address of principal executive offices and zip code)
Emeryville, California 94608
(Address of principal executive offices and zip code)
Registrants telephone number, including area code: (510) 597-6500
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
ITEM 2.01. COMPLETION OF ACQUISITION OF ASSETS
Effective on November 16, 2009, Onyx Pharmaceuticals, Inc. (Onyx), completed its
acquisition of Proteolix, Inc. (Proteolix), pursuant to the Agreement and Plan of Merger,
dated as of October 10, 2009 (the Merger Agreement), among Proteolix, Profiterole
Acquisition Corp., a wholly-owned subsidiary of Onyx (Merger Sub) and Shareholder
Representative Services LLC, as the Stockholders Agent. Pursuant to the terms of the Merger
Agreement, Merger Sub merged with and into Proteolix (the Merger) and Proteolix continued
as the surviving corporation and a wholly owned subsidiary of Onyx. Simultaneous with the Merger,
Proteolixs name was changed to Onyx Therapeutics, Inc. Subject to the terms and conditions of the
Merger Agreement, at the effective time of the Merger (the Effective Time) each issued
and outstanding share of Proteolix capital stock was canceled and converted into the right to
receive the consideration described in the Merger Agreement. In addition, at the Effective Time all
outstanding stock options to purchase Proteolix shares vested in full, were cancelled and converted
into the right to receive the merger consideration for each Proteolix share subject to the option
less the option exercise price, as described in the Merger Agreement.
The total consideration paid by Onyx to Proteolix securityholders at closing consisted of
$276 million in cash, of which $27.6 million was placed in an escrow account and will be held
until December 31, 2010 to secure the indemnification rights of Onyx and other indemnitees with
respect to certain matters, including breaches of representations, warranties and covenants of
Proteolix included in the Merger Agreement. In addition, Onyx may pay up to an additional $575
million in earnout payments upon the receipt of certain regulatory approvals and the satisfaction
of other milestones. Of this amount, Onyx expects the first earnout payment of $40 million to be
payable in 2010, 180 days after completion of enrollment in a clinical study involving relapsed and
refractory multiple myeloma patients. Upon achievement of the first milestone, $4 million of the
first earnout payment will also be contributed to the escrow account. The remaining $535 million
of earnout payments will become payable in up to four additional installments, upon the achievement
of regulatory approvals in the US and Europe within pre-specified timeframes for Proteolixs lead
product candidate, carfilzomib. The second earnout payment of $170 million would be triggered by
the achievement of accelerated marketing approval in the United States for relapsed/refractory
multiple myeloma. The third earnout payment of $65 million would be triggered by marketing approval
in the European Union for relapsed/refractory multiple myeloma. The fourth earnout payment of $150
million would be triggered by marketing approval in the United States for relapsed multiple
myeloma. The final earnout payment, also $150 million, would be triggered by marketing approval for
relapsed multiple myeloma in the European Union. Under certain circumstances, including if Onyx
fails to satisfy its regulatory approval-related diligence obligations under the Merger Agreement,
Onyx may be required to make one or more earnout payments even if the associated regulatory
approvals are not received.
Subject to the terms and conditions set forth in the Merger Agreement, Onyx may, in its sole
discretion, make any of the earnout payments (with the exception of the first earnout payment) that
become payable to former holders of Proteolix preferred stock in the form of cash, shares of Onyx
common stock or a combination thereof. If Onyx elects to issue shares of its common stock (the
Earnout Payment Shares ) in lieu of making an earnout payment in cash, the Earnout Payment Shares
will be valued based on the 10-trading day volume weighted average price for Onyx common stock
commencing six trading days after the public announcement by Onyx of the achievement of the
applicable milestone. In the event that Onyx makes an earnout payment in the form of its common
stock, it expects to rely on the exemption from registration pursuant to Section 4(2) under the
Securities Act of 1933, as amended.
The foregoing summary of the Merger and the terms of the Merger Agreement does not purport to
be complete, and is qualified in its entirety by the terms and conditions of the Merger Agreement,
a copy of which was filed as Exhibit 2.1 to Onyxs Current Report on Form 8-K filed with the
Securities and Exchange Commission on October 13, 2009.
ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS
(a) Financial Statements of Businesses Acquired
The financial statements required by Item 9.01(a) of Form 8-K will be filed by amendment to
this Current Report on Form 8-K not later than seventy-one (71) calendar days after the date that
this Current Report on Form 8-K must be filed.
(b) Pro Forma Financial Information
The pro forma financial statements required by Item 9.01(b) of Form 8-K will be filed by
amendment to this Current Report on Form 8-K not later than seventy-one (71) calendar days after
the date that this Current Report on Form 8-K must be filed.
(d) Exhibits.
Number | Description | |
99.1
|
Press Release, dated November 16, 2009, titled Onyx Pharmaceuticals Completes Acquisition of Proteolix, Inc. |
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: November 16, 2009 | ONYX PHARMACEUTICALS, INC. |
|||
By: | /s/ Suzanne M. Shema | |||
Suzanne M. Shema | ||||
Senior Vice President and General Counsel |
EXHIBIT INDEX
Number | Description | |
99.1
|
Press Release, dated November 16, 2009, titled Onyx Pharmaceuticals Completes Acquisition of Proteolix, Inc. |